Jessica Ailani, MD, FAAN, Medstar Georgetown University Hospital, Washington, DC, discusses the findings of a post-hoc analysis of ubrogepant safety and tolerability across various demographic and clinical subpopulations. Ubrogepant is an oral calcitonin gene–related peptide (CGRP) receptor antagonist, known as a gepant, FDA approved for acute migraine treatment in adults. The pooled population of over 1900 patients from the ACHIEVE I and II trials (NCT02828020; NCT02867709) showed that the safety and tolerability of ubrogepant were consistent across all subgroups. Rates of adverse events were independent of age group, race, gender, BMI, and anxiety/depression medication use. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Consulting: (Honoraria for independent consulting) Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, Medscape
Ownership of Stocks: CtrM
Speakers Bureau: (Honoraria for promotional speaking) Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva
Editorial services: (Honoraria) Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, SELF (medical reviewer)
Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, Zosano